Hair loss affects approximately 50% of men by age 50 and approximately 40% of women by age 70. Effective hair loss treatment begins with accurate diagnosis. At Advanced Vitality Group, hair restoration programs start with a clinical evaluation and laboratory assessment to establish what is driving the hair loss before any treatment is initiated.
Hair Restoration: Evidence-Based Medical Treatment for Hair Loss in Men and Women
Hair loss affects approximately 50% of men by age 50 and approximately 40% of women by age 70. Effective hair loss treatment begins with accurate diagnosis. At Advanced Vitality Group, hair restoration programs start with a clinical evaluation and laboratory assessment to establish what is driving the hair loss before any treatment is initiated.
Hair loss affects approximately 50% of men by age 50 and approximately 40% of women by age 70. The most prevalent cause — androgenetic alopecia (AGA), also called male or female pattern hair loss — is a well-characterized, hormonally driven condition with multiple FDA-approved treatment options and decades of clinical trial evidence. Effective hair loss treatment begins with accurate diagnosis: not all hair loss is androgenetic alopecia, and treating the wrong cause wastes time and delays recovery. At Advanced Vitality Group, hair restoration programs start with a clinical evaluation and laboratory assessment to establish what is driving the hair loss before any treatment is initiated.
Key Takeaways
Androgenetic alopecia affects ~50% of men by age 50 and ~40% of women by age 70 — it is the most common cause of progressive hair loss.
FDA-approved treatments for AGA include topical minoxidil (men and women) and oral finasteride (men); both have large randomized controlled trial evidence bases.
Oral minoxidil at 0.25–5 mg/day is emerging as an effective alternative for patients who find topical application inconvenient — confirmed in a 2021 systematic review.
Iron deficiency (low ferritin), thyroid dysfunction, and vitamin D deficiency are correctable causes of hair loss that must be ruled out before or alongside AGA treatment.
PRP for androgenetic alopecia has multiple positive RCTs supporting its use; it is not FDA-approved for this indication but is autologous (derived from the patient's own blood).
Finasteride requires physician evaluation, risk discussion, and monitoring — sexual side effects occur in ~2–4% of users; post-finasteride syndrome remains debated in the literature.
Understanding What Drives Hair Loss
Androgenetic Alopecia: The Mechanism
Androgenetic alopecia results from the action of dihydrotestosterone (DHT) on genetically susceptible hair follicles. In the scalp, the enzyme 5α-reductase (types 1 and 2) converts testosterone to DHT. DHT binds to androgen receptors in hair follicle dermal papilla cells, initiating a cascade that progressively shortens the anagen (active growth) phase of the hair cycle — from its normal 2–6 years to months or weeks — while extending the telogen (resting) phase. Over successive cycles, the follicle produces progressively shorter, thinner, and less pigmented hair (miniaturization) until it eventually becomes incapable of producing visible terminal hair.
In men, this produces the characteristic frontotemporal recession and vertex thinning of the Hamilton-Norwood scale. In women, the pattern is typically diffuse thinning across the crown with preservation of the frontal hairline (Ludwig scale). The genetic susceptibility involves variants across multiple genes, including the androgen receptor gene on the X chromosome — which is why maternal grandfather's hair pattern has historically been considered predictive, though the genetics are polygenic and more complex than this single-gene model.
Secondary Causes of Hair Loss: Identification Is Critical
Not all hair loss is AGA. Several common, correctable conditions produce significant hair thinning and are frequently missed in standard workups:
Iron deficiency (with or without anemia)
Ferritin below 30–70 ng/mL (threshold varies across studies) is associated with telogen effluvium — diffuse hair shedding triggered by metabolic stress. Iron is required for ribonucleotide reductase in hair matrix cell division, and deficiency disrupts the hair cycle. Correcting ferritin to adequate levels frequently produces measurable improvement in shedding within 3–6 months. A 2009 review (Trost LB et al., Journal of the American Academy of Dermatology) found that iron deficiency was the most commonly identified nutritional cause of hair loss in women.
Thyroid dysfunction
Both hypothyroidism and hyperthyroidism produce diffuse hair thinning. Hypothyroidism reduces hair follicle mitotic activity and prolongs the telogen phase. Hyperthyroidism accelerates the hair cycle, producing increased shedding. TSH, Free T3, and Free T4 are evaluated in patients with diffuse or rapid-onset hair loss — thyroid-related hair loss typically improves substantially with appropriate thyroid treatment.
Vitamin D deficiency
Vitamin D receptors (VDRs) are expressed in hair follicle keratinocytes and play a role in initiating the anagen phase. VDR mutations in humans produce alopecia. Observational studies associate low vitamin D with alopecia areata and telogen effluvium. Correcting deficiency (25-OH vitamin D below 20 ng/mL) is a standard component of comprehensive hair loss evaluation.
Nutritional adequacy
Severe caloric restriction, very low protein intake, and deficiencies in zinc or biotin (the latter in the context of documented deficiency, not routine supplementation) can produce telogen effluvium. Crash dieting is one of the most common triggers of significant hair shedding in women.
Alopecia areata
An autoimmune condition producing patchy or total hair loss through immune-mediated follicular destruction. Requires specific diagnosis and treatment distinct from AGA.
FDA-Approved Hair Loss Treatments
Topical Minoxidil (2% and 5%)
Minoxidil is the only FDA-approved topical treatment for androgenetic alopecia in both men and women. Originally developed as an antihypertensive drug, its hair growth effects were discovered as a side effect. Minoxidil's mechanism in AGA involves: vasodilation of scalp arterioles (improving follicular oxygen and nutrient delivery), opening of potassium channels in follicular cells, prolongation of the anagen phase, and upregulation of VEGF (vascular endothelial growth factor) in dermal papilla cells — stimulating follicular vascularization.
Clinical evidence: A 48-week randomized controlled trial (Olsen EA et al., Journal of the American Academy of Dermatology, 2002) found that 5% topical minoxidil produced significantly greater hair regrowth than 2% minoxidil and placebo in men with AGA. The 5% formulation is now standard first-line treatment for men. The 2% formulation is FDA-approved for women with AGA and has RCT evidence for efficacy. Minoxidil requires continuous use — hair loss resumes within months of discontinuation as the follicles return to their pre-treatment state.
Oral Minoxidil (Off-Label)
Low-dose oral minoxidil (0.25–5 mg/day in men; 0.25–1.25 mg/day in women) has emerged as an effective alternative for patients who find topical application inconvenient or who have not responded optimally to topical treatment. A 2021 systematic review (Randolph M, Tosti A, Journal of the American Academy of Dermatology) confirmed efficacy across doses of 0.25–5 mg/day, with the most common side effects being hypertrichosis (unwanted facial and body hair, dose-dependent) and fluid retention. Oral minoxidil requires physician evaluation and blood pressure monitoring due to cardiovascular effects. It is not FDA-approved specifically for hair loss (it is approved for hypertension), but is prescribed off-label based on the available clinical evidence.
Finasteride 1 mg/day
Finasteride is an oral 5α-reductase type 2 inhibitor FDA-approved for male androgenetic alopecia. At 1 mg/day, it reduces scalp DHT levels by approximately 60–70%, significantly slowing the progression of follicular miniaturization and, in many patients, producing measurable hair regrowth. A landmark 2-year randomized controlled trial of 1,553 men (Finasteride Male Pattern Hair Loss Study Group, Journal of the American Academy of Dermatology, 1998) found that 83% of finasteride-treated men maintained or improved their hair count at two years, compared with only 28% in the placebo group.
Finasteride requires physician prescription and a full risk discussion. Sexual side effects — decreased libido, erectile dysfunction, ejaculatory dysfunction — are reported in approximately 2–4% of users in clinical trials (vs. approximately 2% placebo rate). Post-finasteride syndrome — persistent sexual, cognitive, or emotional side effects persisting after discontinuation — has been reported in a subset of men; its prevalence and causality remain under investigation in the medical literature. PSA testing is recommended before initiation in men over 40, as finasteride reduces PSA by approximately 50% and may affect prostate cancer screening interpretation. At Advanced Vitality Group, finasteride is prescribed with full evidence disclosure, risk discussion, and appropriate monitoring.
Dutasteride 0.5 mg/day (Off-Label)
Dutasteride inhibits both type 1 and type 2 5α-reductase, producing greater DHT suppression (> 90%) than finasteride. It is FDA-approved for benign prostatic hyperplasia and used off-label for AGA. A meta-analysis of 7 RCTs found dutasteride superior to finasteride for AGA outcomes, with a similar side effect profile. It is used in clinical practice for patients who have not responded adequately to finasteride, with the same monitoring requirements.
Emerging Evidence-Based Options
Platelet-Rich Plasma (PRP)
PRP is prepared by centrifuging a small sample of the patient's own blood to concentrate platelets — and the growth factors they contain (PDGF, VEGF, TGF-β, IGF-1) — and injecting this autologous concentrate into the scalp. Multiple randomized controlled trials have demonstrated significant improvements in hair density and hair shaft diameter with PRP versus placebo injections. A 2019 systematic review (Gupta AK, Carviel J) found consistent positive findings across studies, with PRP significantly outperforming placebo for both hair density and thickness metrics. Protocol variables — platelet concentration, activation method, injection spacing, and volume — affect outcomes and limit direct comparison across studies. PRP is not FDA-approved specifically for hair loss but is used clinically based on the available evidence, with full patient disclosure of its status.
Low-Level Laser Therapy (LLLT)
LLLT devices operating at 650–670 nm — including FDA-cleared laser combs and caps — have evidence from multiple RCTs for hair density improvement in AGA. A meta-analysis of 11 RCTs (Afifi L et al., Dermatologic Surgery, 2017) found significant improvements in hair density and thickness with LLLT compared to sham devices. LLLT's mechanism involves photobiomodulation — absorption of low-level red light by mitochondrial cytochrome c oxidase in follicular cells, increasing ATP production and cellular metabolic activity. LLLT is most effective as an adjunct to pharmacological treatment rather than a standalone therapy.
Hair Loss Treatment Decision Framework
| Treatment | FDA Status | Evidence Level | Best For | Key Considerations |
|---|---|---|---|---|
| Topical minoxidil 5% (men) | FDA-approved | Grade A | First-line AGA men | OTC; requires continuous daily use |
| Topical minoxidil 2% (women) | FDA-approved | Grade A | First-line AGA women | OTC; requires continuous use |
| Oral minoxidil (0.25–5 mg) | Off-label | Grade B | Topical non-responders; convenience preference | Rx; CV evaluation; hypertrichosis risk |
| Finasteride 1 mg/day | FDA-approved (men) | Grade A | Male AGA, all stages | Rx; full risk discussion; PSA baseline; not for women of childbearing age |
| Dutasteride 0.5 mg/day | Off-label | Grade B | Finasteride non-responders (men) | Rx; same risk profile; greater DHT suppression |
| PRP scalp injections | Not FDA-approved (autologous) | Grade B | AGA adjunct or mild cases | Autologous; multiple sessions; protocol variability |
| LLLT devices (FDA-cleared) | FDA-cleared | Grade B | AGA adjunct | Best combined with pharmacological treatment |
| Hair transplant (FUE/FUT) | Surgical procedure | Grade A (for appropriate candidates) | Stable AGA with adequate donor hair | Surgical consultation required; permanent |
This content is for educational purposes only. It does not replace consultation with a licensed clinician and does not constitute medical advice. All aesthetic and medical treatment decisions require individual clinical evaluation and physician oversight. Results vary by patient. Do not self-administer any medication, compound, or treatment based on this article.
Frequently Asked Questions
Scientific References
- Olsen EA, et al. “A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo.” Journal of the American Academy of Dermatology. 2002;47(3):377–385.
- Finasteride Male Pattern Hair Loss Study Group. “A randomized, placebo-controlled trial of finasteride in men with androgenetic alopecia.” JAAD. 1998;39(4):578–589.
- Randolph M, Tosti A. “Oral minoxidil treatment for hair loss: A review of efficacy and safety.” JAAD. 2021;84(3):737–746.
- Gupta AK, Carviel J. “A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia.” Dermatologic Surgery. 2016;42(12):1335–1339.
- Afifi L, et al. “Systematic review of low-level laser therapy for androgenetic alopecia.” Dermatologic Surgery. 2017;43(3):333–339.
- Trost LB, et al. “The diagnosis and treatment of iron deficiency and its potential relationship to hair loss.” JAAD. 2006;54(5):824–844.
Start Your Hair Restoration Journey
Schedule a consultation to discuss your hair loss evaluation and create an evidence-based treatment plan.